Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][10] Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [3][4] - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [9] - A exclusivity period is set from the signing date until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [9] Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [11][13] - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [11][13] Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [15] - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% year-on-year to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [18][19]
301290 重大资产重组！